Medication-related osteonecrosis of the jaw (MRONJ): treatment and prevention

bisphosphonate

This Cochrane review of interventions for the prevention and treatment of medication-related osteonecrosis of the jaw (MRONJ) identified 5 trials. Three were related to prevention and two to treatment providing limited evidence to support interventions. More high quality studies are needed.

[read the full story...]

Bisphosphonate-related osteonecrosis of the jaw treatments– little evidence available

bisphosphonate

This Cochrane review of bisphosphonate related osteonecrosis of the jaw only identified one small RCT. The trial compared the use of hyperbaric oxygen (HBO) as an adjunct to standard care. While it suggested a benefit for HBO it was under powered and at high riisk of bias

[read the full story...]

Medication related osteonecrosis of the jaw

bisphosphonate

Thirteen studies were included in this review of medication related osteonecrosis of the jaw. The majority were case series ( 9) with the risk of osteonecrosis after tooth extraction being higher in those taking IV bisphosphonates ( 3.2% (95% CI: 1.7–4.7%) than those on oral bisphosphonates 0.15% (95% CI: 0.0–0.36%).

[read the full story...]

Bisphosphonate-related osteonecrosis of the jaw treatments

bisphosphonate

97 papers describing 4879 cases of bisphosphonate-related osteonecrosis were included in this review. A wide range of management approaches were identified but the quality of the available evidence is limited.

[read the full story...]

Avascular necrosis of the jaws (BRONJ): risk and incidence low in the UK

bisphosphonate

This 2 year long prospective study of new cases of BRONJ presenting at oral surgery, oral medicine, oral and maxillofacial surgery units, and dental hospitals provides a rough estimate of 508–793 new cases/year across the UK.

[read the full story...]